see http://www.cellmedicine.com

See the rest here:
Stem Cell Therapy for Critical Limb Ischemia

Stem cell therapy enables legendary Ennis, Texas football coach to see his son in Super Bowl XLV

Continue reading here:
Stem Cell Therapy MS: Sam Harrell and The Superbowl

For the first time in Australia, researchers from University of Melbourne and Monash Institute of Medical Research have converted diseased skin cells into stem cells. Researchers have completed the study by using skin biopsies from patients with the rare genetic disease Friedreich Ataxia (FA).

Read more:
Visions Episode 92: Stem Cells Discovery

Two dogs in Polk County are getting stem cell therapy. The treatment is designed to help older dogs that have problems walking.

View original post here:
Dogs now getting stem cell therapy

Video sent to the XCell-Center by dementia patient, Guilia Serafini, documenting her improvements following stem cell therapy.

Go here to read the rest:
Stem Cell Therapy For Alzheimer's/Dementia

Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined.

Link:
Clinical Advances in Adult Stem Cell Therapy: Dr. Jorge Paz

Researchers from the Shanghai Institutes for Biological Sciences (SIBC) in China have identified a powerful compound in birch bark called betulin that helps lower cholesterol and prevent both diabetes and obesity. And betulin works particularly better than the statin drug lovastatin at lowering cholesterol, except without the harmful side effects.

Dr. Bao-Liang Song and his colleagues from SIBC tested the effects of betulin and found that it specifically targets the genes responsible for making harmful blood fats like triglycerides by effectively lowering their activity and protecting against disease. And since the compound is "abundant in birch bark," it has the potential to revolutionize the way blood fat levels are managed.

Concerning cholesterol levels, betulin was shown to lower lipid levels more effectively than lovastatin. And insulin-wise, betulin helps keep artery walls free and clear of build-ups and blockages, also known as atherosclerosis. Read more...

Ayurtox for Body Detoxification

http://www.cellmedicine.com

Go here to see the original:
Stem Cell Therapy for Type II Diabetes

The "Queen of Soul" Aretha Franklin has reportedly been given less than a year to live by her doctors. She is reportedly suffering from "incurable advanced pancreatic cancer" according to The National Inquirer, a source that should perhaps be taken with a grain of salt. But CBS News is also running the story, along with other mainstream media outlets.

The reason her cancer is "advanced," of course, is because her doctors never told her the truth about pancreatic cancer, which is that through significant changes in diet and lifestyle, even pancreatic cancer can be reversed. I've seen numerous pancreatic cancer patients who reversed their condition by turning to natural cancer therapies such as Gerson Therapy, which is based on daily juicing of fresh vegetables and fruit, cleansing detoxificatiohttp://www.blogger.com/img/blank.gifn of the body's organs, and improving the nutritional density of foods. (http://www.Gerson.org)

The cancer industry is terrified that people might discover these "natural cures" to cancer because this would wipe out the highly lucrative chemotherapy, radiation and surgical treatments that remain the profit centers for mainstream cancer treatment centers. There is a reason, after all, why U.S. authorities ran all the alternative cancer clinics out of the country and arrested the alternative doctors who were curing the most patients. Such cures simply cannot be allowed in America because they threaten the profits of the cancer industry! Read more...

Ayurtox for Body Detoxification

International Stem Cell Corporation Reports First Quarter Revenue of $1.5 Million on Strong Initial Sales of Skin Care Products and Strong Growth of Research Product Sales

International Stem Cell Corporation (OTCBB: ISCO) (ISCO) announces that revenue in the first quarter of 2011 was $1.5 million, compared with revenue of $273,000 in the first quarter of 2010. The increase was primarily due to $1.1 million in sales of Lifeline Skin Care products achieved in the pilot direct-to-consumer launch. Adding to the revenue growth was a 35% increase over the prior year in sales of human cell culture research products from subsidiary Lifeline Cell Technology.

ISCO also disclosed that it is delaying the filing of its Report on Form 10-Q for the period ending March 31, 2011 in order to resolve an accounting question as described below.

Shortly before the scheduled date for filing the 10-Q, ISCO identified an issue related to whether a technical interpretation of certain accounting guidance found in FASB ASC Topic 815, Derivatives and Hedging could require a change in the manner ISCO has historically accounted for the value of warrants originally issued as compensation to brokers working for the placement agent in the Company's 2007 initial public offering.

The accounting question is highly technical in nature and would have no impact on cash or revenues, but relates solely to the non-cash accounting for warrants issued several years ago. Rather than publish information that might be subject to further revision, ISCO has elected to delay the filing of its 10-Q until a decision can be made as to whether or not adjustments will need to be made and, if so, exactly what the accounting entries will be. The Company is committed to resolving this question as promptly as possible and will disclose the conclusion in the 10-Q.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

Forward-looking Statements

Statements pertaining to anticipated developments, anticipated resolution of the accounting question, and opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, the application of accounting guidance, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Stem Cells Used in the USA !!!

Read the original:
Stem Cell Therapy for Peripheral Artery Disease

Heart Failure Patient After Adult Stem Cell Therapy - http://www.cellmedicine.com. 3 hours ago.

Originally posted here:
New Cell Therapy to Prevent Organ Rejection